MedPath
HSA Approval

EBGLYSS SOLUTION FOR INJECTION IN PRE-FILLED PEN 250MG/2ML

SIN17229P

EBGLYSS SOLUTION FOR INJECTION IN PRE-FILLED PEN 250MG/2ML

EBGLYSS SOLUTION FOR INJECTION IN PRE-FILLED PEN 250MG/2ML

May 2, 2025

DKSH SINGAPORE PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantDKSH SINGAPORE PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INJECTION, SOLUTION

SUBCUTANEOUS

Medical Information

D11AH10

Manufacturer Information

DKSH SINGAPORE PTE. LTD.

Eli Lilly and Company

Active Ingredients

Lebrikizumab

250 mg/2 mL

Lebrikizumab

Documents

Package Inserts

EBGLYSS Solution for Injection in Pre-filled Pen PI.pdf

Approved: May 2, 2025

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

EBGLYSS SOLUTION FOR INJECTION IN PRE-FILLED PEN 250MG/2ML - HSA Approval | MedPath